Biotech Values

[DewDiligence]

Remember Recothrom…the gem from Zymogenetics? Well, BMY just offloaded it to MDCO, a company who seems willing to take—and pay good money for—whatever products and product candidates Big Pharma doesn’t want:

http://finance.yahoo.com/news/medicines-company-bristol-myers-squibb-120000013.html

The Medicines Company will pay Bristol-Myers Squibb an upfront collaboration payment of $105 million and an upfront option fee of $10 million. The Medicines Company has also agreed to pay Bristol-Myers Squibb a tiered royalty on annual net revenues of Recothrom during the two-year collaboration term. Bristol-Myers Squibb will retain responsibility for the manufacturing of Recothrom and will be The Medicine Company's exclusive supplier of Recothrom during the term of the agreement. The option enables The Medicines Company to acquire the Recothrom assets for a purchase price based on average net sales during the two-year collaboration term.